Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 12 clients • 13 examiners • 13 art units • 0 of 13 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Entralta has 15 pending office actions in Biotechnology & Pharmaceuticals and 792 career applications. The profile reflects an active life-sciences practice with a recorded application history supporting the current docket.
The resolved allowance rate is 82.31%, with an average of 2.67 office actions per allowance. The allowance figure describes resolved outcomes, while the action average indicates the examination activity associated with matters that reached allowance.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (23%) |
| §103 only | 1 (8%) |
| Double-patenting + other | 4 (31%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILLIGAN, CHRISTOPHER L | 1 | 57.5% | +40.3% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| HOFFMAN, ALEXANDER JOSEPH | 1 | 0.0% | +0.0% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| ARON, KIMBERLY A | 1 | 54.7% | +34.3% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
| PINDERSKI, JACQUELINE M | 1 | 26.8% | +45.4% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767859 | ANTI-CANCER LEUCINE-RICH PEPTIDES AND USES THEREOF | DABKOWSKI, ERINNE R | 2d overdue |
| 19077031 | AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR AUTOMATED COMPLETION OF HEALTHCARE PROCESSES | GILLIGAN, CHRISTOPHER L | — |
| 18858722 | FORMULATION FOR TREATING URINARY SYSTEM DISORDERS | SCOTLAND, REBECCA LYNN | — |
| 18835014 | SENESCENT CELL SURFACE MARKERS | HOFFMAN, ALEXANDER JOSEPH | — |
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | — |
| 18349884 | AIRWAY DEVICE | PINDERSKI, JACQUELINE M | — |
| 18030996 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17472370 | DETECTABLE ARRAYS, SYSTEMS FOR DIAGNOSIS, AND METHODS OF MAKING AND USING THE SAME | BUNKER, AMY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285645 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | CHANG, KYUNG SOOK | 86d overdue |
| 18770847 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | CHERNYSHEV, OLGA N | 28d |
| 19077031 | AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR AUTOMATED COMPLETION OF HEALTHCARE PROCESSES | GILLIGAN, CHRISTOPHER L | — |
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | — |
| 18595355 | METHODS OF TREATMENT USING BCN057, BCN077 AND ANALOGS | COPPINS, JANET L | — |
| 18285641 | BIOACTIVE PRODUCTS | SWIFT, CANDICE LEE | — |
| 18349884 | AIRWAY DEVICE | PINDERSKI, JACQUELINE M | — |
| 18030996 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| Client (Assignee) | Pending OAs |
|---|---|
| King's College London | 2 |
| Optrahealth Inc. | 1 |
| Watershed Medical, Inc. | 1 |
| Sens Research Foundation | 1 |
| Biomed Industries | 1 |
| OCULOGENEX INC. | 1 |
| Bcn Biosciences LLC | 1 |
| Victor Tets | 1 |
| WATERSHED MEDICAL INC | 1 |
| Kb Pro, LLC | 1 |
| InnoMed Technologies, Inc. | 1 |
| Entopsis, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 3683 | 1 |
| 1615 | 1 |
| 1677 | 1 |
| 1675 | 1 |
| 1633 | 1 |
| 1628 | 1 |
| 1657 | 1 |
| 1613 | 1 |
| 3785 | 1 |
| 1658 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19077031 | AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR AUTOMATED COMPLETION OF HEALTHCARE PROCESSES | Optrahealth Inc. | GILLIGAN, CHRISTOPHER L | 3683 | §101§103§112 | Non-Final OA | — | Pending | Mar 11, 2025 |
| 18858722 | FORMULATION FOR TREATING URINARY SYSTEM DISORDERS | Watershed Medical, Inc. | SCOTLAND, REBECCA LYNN | 1615 | §102§103§112Other | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18835014 | SENESCENT CELL SURFACE MARKERS | Sens Research Foundation | HOFFMAN, ALEXANDER JOSEPH | 1677 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18770847 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | BIOMED INDUSTRIES, INC. | CHERNYSHEV, OLGA N | 1675 | §102DP | Final Rejection | 28d | Pending | Jul 12, 2024 |
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | Oculogenex Inc. | ARON, KIMBERLY A | 1633 | §102§112 | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18595355 | METHODS OF TREATMENT USING BCN057, BCN077 AND ANALOGS | Bcn Biosciences LLC | COPPINS, JANET L | 1628 | §102§112DP | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18285641 | BIOACTIVE PRODUCTS | Victor Tets | SWIFT, CANDICE LEE | 1657 | §102§103§112DP | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18285645 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | Watershed Medical Inc. | CHANG, KYUNG SOOK | 1613 | §103§112DP | Final Rejection | 86d overdue | Pending | Oct 04, 2023 |
| 18349884 | AIRWAY DEVICE | Kb Pro, LLC | PINDERSKI, JACQUELINE M | 3785 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18030996 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | King'S College London | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112Other | Non-Final OA | — | Pending | Apr 08, 2023 |
| 18075158 | ANTIMICROBIAL COATING CONTAINING ERYTHRITOL | Innomed Technologies, Inc. | STIMPERT, PHILIP EARL | 3783 | §103 | Final Rejection | — | Pending | Dec 05, 2022 |
| 17767859 | ANTI-CANCER LEUCINE-RICH PEPTIDES AND USES THEREOF | King'S College London | DABKOWSKI, ERINNE R | 1654 | §103§112Other | Final Rejection | 2d overdue | Pending | Apr 08, 2022 |
| 17472370 | DETECTABLE ARRAYS, SYSTEMS FOR DIAGNOSIS, AND METHODS OF MAKING AND USING THE SAME | Entopsis, Inc. | BUNKER, AMY M | 1684 | §101§103 | Final Rejection | — | Pending | Sep 10, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial82.3% of resolved applications prosecuted by Entralta were allowed, across 792 applications in USPTO records.
2.67 office actions per allowed application on average.
13 pending office actions as of October 2026, for 12 clients, before 13 examiners in 13 art units.
